Cargando…
Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy
AIM: To explore the metabolic phenotype of obesity-related secondary hypogonadism (SH) in men pre-replacement and post-replacement therapy with long-acting intramuscular (IM) testosterone undecanoate (TU). METHODS: A prospective observational pilot study on metabolic effects of TU IM in male obesity...
Autores principales: | Dimitriadis, Georgios K., Randeva, Harpal S., Aftab, Saboor, Ali, Asad, Hattersley, John G., Pandey, Sarojini, Grammatopoulos, Dimitris K., Valsamakis, Georgios, Mastorakos, Georgios, Jones, T. Hugh, Barber, Thomas M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845623/ https://www.ncbi.nlm.nih.gov/pubmed/29396841 http://dx.doi.org/10.1007/s12020-017-1516-x |
Ejemplares similares
-
A new oral testosterone undecanoate therapy comes of age for the
treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020) -
Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials
por: Lachance, Sylvain, et al.
Publicado: (2015) -
Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010) -
Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021) -
Placental CRH as a Signal of Pregnancy Adversity and Impact on Fetal Neurodevelopment
por: Kassotaki, Ifigeneia, et al.
Publicado: (2021)